ArticleDiabetes care2024
The Difference Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and Risk of Diabetic Microvascular Complications Among Adults With Diabetes: A Population-Based Cohort Study.
Article in Diabetes care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 33 citations in OpenAlex.
- Healthy diet and slower biological aging as protective factors against microvascular complications in type 2 diabetes.GeroScience · 2026Article
- Association between extracellular-to-total body water ratio and eGFR decline in diabetic kidney disease: a longitudinal cohort study.Clinical and experimental nephrology · 2026Observational
- Selective glomerular hypofiltration is associated with glucometabolic disturbances in the general population.Journal of internal medicine · 2026Article
- Association Between Differences in Estimated GFR by Creatinine Vs. Cystatin C and Stroke Outcomes: Results From the Third China National Stroke Registry.CNS neuroscience & therapeutics · 2026Article
- Safety of anagliptin/metformin combination tablets evaluated by non-inferiority between pre- and post-serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY).Journal of diabetes investigation · 2026Article
- The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.Neurodegenerative disease management · 2026Article
- The association of estimated glucose disposal rate with white matter hyperintensities: A large prospective cohort study.The journal of prevention of Alzheimer's disease · 2026Article
- A nomogram prediction model incorporating noninvasive lens AGEs and conventional biochemical indicators for assessing and predicting diabetic kidney disease.Scientific reports · 2026Article
- Serum cystatin C as a biomarker for diabetic retinopathy and its role in diabetic retinopathy-diabetic kidney disease comorbidity.Journal of translational medicine · 2026Article
- Article
- Plasma proteomics based on machine learning predict the early risk of kidney outcomes in patients with DKD: a prospective cohort study from UK Biobank.Frontiers in nephrology · 2026Article
- Renal Biomarkers as Predictors of Renal Damage in Patients With Type 2 Diabetes.BioMed research international · 2026Article
- Discovery and validation of a multi-protein panel for predicting non-fatal major adverse cardiovascular events in diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Diagnostic value of urinary albumin creatinine ratio in predicting vision-threatening diabetic retinopathy in patients with diabetes: a systematic review and Meta-analysis.International journal of ophthalmology · 2026Article
- Cystatin C-based equations: Enhancing accuracy in kidney function tests for type 2 diabetes.World journal of nephrology · 2025Article
- The G-allele of rs10830963 inInternational journal of molecular sciences · 2025Article
- Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF-15 With Adverse Outcomes in Diabetes Mellitus.Journal of cachexia, sarcopenia and muscle · 2025Article
- Association of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate with cerebral small vessel disease: A large prospective cohort study.The journal of prevention of Alzheimer's disease · 2025Article
- Monitoring Sarcopenia With Incretin Receptor Activator Treatment.Journal of diabetes · 2025Article
- Emerging Biomarkers and Advanced Diagnostics in Chronic Kidney Disease: Early Detection Through Multi-Omics and AI.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe impact of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFRdiff) on diabetic microvascular complications (DMCs) remains unknown. We investigated the associations of eGFRdiff with overall DMCs and subtypes, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic neuropathy (DN). RESEARCH DESIGN AND
methodsThis prospective cohort study included 25,825 participants with diabetes free of DMCs at baseline (2006 to 2010) from the UK Biobank. eGFRdiff was calculated using both absolute difference (eGFRabdiff) and the ratio (eGFRrediff) between cystatin C- and creatinine-based calculations. Incidence of DMCs was ascertained using electronic health records. Cox proportional hazards regression models were used to evaluate the associations of eGFRdiff with overall DMCs and subtypes.
resultsDuring a median follow-up of 13.6 years, DMCs developed in 5,753 participants, including 2,752 cases of DR, 3,203 of DKD, and 1,149 of DN. Each SD decrease of eGFRabdiff was associated with a 28% higher risk of overall DMCs, 14% higher risk of DR, 56% higher risk of DKD, and 29% higher risk of DN. For each 10% decrease in eGFRrediff, the corresponding hazard ratios (95% CIs) were 1.16 (1.14, 1.18) for overall DMCs, 1.08 (1.05, 1.11) for DR, 1.29 (1.26, 1.33) for DKD, and 1.17 (1.12, 1.22) for DN. The magnitude of associations was not materially altered in any of the sensitivity analyses.
conclusionsLarge eGFRdiff was independently associated with risk of DMCs and its subtypes. Our findings suggested monitoring eGFRdiff in the diabetes population has potential benefit for identification of high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.